I had one patient who, after several months of appropriate dosage and careful monitoring, lost a significant amount of weight
- Some individuals have a germline BAP1 mutation in one of the alleles, which manifests as multiorgan tumor predisposition syndrome,54 with a greater risk of mesothelioma, renal carcinoma, cholangiocarcinoma, basal cell carcinoma, and, frequently, cutaneous and uveal melanoma
The ZEUS clinical trial (NCT05021835) is a research study to look at how Ziltivekimab works compared to placebo in people with cardiovascular disease, chronic kidney disease and inflammation.The study is conducted to see if ziltivekimab reduces the risk of having cardiovascular events (for example heart attack and stroke) in people with cardiovascular disease (CVD), chronic kidney disease (CKD) and inflammation
[Abstract] Life Sci
[DOI] [PMC free article] [PubMed] [Google Scholar] Bartosz, G